glp-1 malnutrition Application of nutrition interventions with based therapies: A narrative review of the challenges and solutions Nutritional Approaches to Enhance GLP-1

doi:10.1146/annurev.nutr.24.012003.132440

Baeshen NA, Baeshen MN, Sheikh A, Bora RS, Ahmed MM, Ramadan HA, et al

Important Wegovy lawsuit updates July 2026: There are now 3,848 active claims in the Wegovy MDL

This dilemma is key and will define your product and business

Raghav SK, Gupta B, Agrawal C, Goswami K, Das HR

Because each of the major studies for SGLT2is, GLP1-RAs, and nsMRAs added these newer therapies to participants on the maximum label or tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), it is suggested that cardiorenal protective therapy begin with either an ACEi or an ARB, titrated to either the label maximum or the maximum tolerated dose (see Table 1 for list of currently approved ACEi and ARB in Canada and the maximally recommended dosing)